Pear Therapeutics loses 97% of its market capitalization since 2021, explores strategic alternatives

Pear Ther­a­peu­tics explor­ing sale, oth­er ‘strate­gic alter­na­tives’ (Mobi­Health News): Pre­scrip­tion dig­i­tal ther­a­peu­tics com­pa­ny Pear Ther­a­peu­tics is explor­ing “strate­gic alter­na­tives,” includ­ing a pos­si­ble com­pa­ny sale, merg­er or acqui­si­tion. In a press release, the com­pa­ny said it hired a finan­cial advi­sor to look into actions that could “max­i­mize share­hold­er val­ue.” That includes a poten­tial sale, M&A, divestiture…

Read More